Pegylation: a novel process for modifying pharmacokinetics.
By J. M. Harris, N. Martin, M. Modi. Clinical Pharmacokinetics, 2001
841 citations recorded by the source corpus.
Subfields: Epidemiology, Molecular Biology, Rheumatology
View Paper: https://www.semanticscholar.org/paper/6644b87681468c63746c20a0bf6d165374c77533
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Epidemiology
In Molecular Biology
- G. Walsh
- Jennifer L. West
- You Han Bae
- A. Molinari
- R. Jefferis
- Kinam Park
- Naomi J. Halas
- Giuseppina Bozzuto
In Rheumatology
Citations in the corpus
- Smart Nanoparticles for Drug Delivery Application: Development of Versatile Nanocarrier Platforms in Biotechnology and Nanomedicine (2019, background): “As reported for other nanocarriers, QDs also experience nonspecific uptake by the RES.”
- Liposomes as nanomedical devices (2015, background): “103,104 Finally, the presence of PEG in liposome formulations prevents aggregation, favors the formation of small, monodisperse particles, and increases the EPR effect, due to the extended circulation time and escape from the RES.”
- Post-translational modifications in the context of therapeutic proteins (2006, positive): “The covalent attachment of PEG to the polypeptide backbone represents an increasingly common form of engineerin”
- Thermo- and pH-Responsive Hydrogel-Coated Gold Nanoparticles (2004, background): “Within the molecular structure shown, the thiol group at one end of the chain is used to anchor the initiator to the surface of the AuNP, and the PEG group at the other end is used initially to stabilize the AuNPs in solution and later to lend biocompatibility to the system (Harris et al. 2001).”
- Photo-thermal tumor ablation in mice using near infrared-absorbing nanoparticles. (2004, background): “It has been demonstrated that stealthing liposomes as well as other biomolecules and materials with PEG suppresses immunogenic responses, improving blood circulation times and overall material/implant performance [16,17].”
- Targeted drug delivery to tumors: Myths, reality and possibility (2011, positive): “To this end, PEGylation has been used extensively to modify the pharmacokinetics of the drug itself and/or the nanoparticles [56].”